Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its ...

Following the disappointment of a multiple sclerosis (MS) trial readout this week, Sanofi has signed a pair of deals in the ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...

The PERSEUS trial was a global, double-blind, randomized Phase 3 study comparing tolebrutinib to placebo in PPMS patients.

ADEL Inc., a biopharma company, has entered into an exclusive worldwide license agreement with Sanofi for the development and ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Kyverna Therapeutics announced positive topline data from a phase II trial of mivocabtagene autoleucel, a chimeric antigen ...